Last updated August 27, 2026
Key finding
Estimated difference -16.7 percentage points; P = 0.0001
This study evaluated the efficacy of Semaglutide 2.4 mg in adolescents with obesity, finding significant improvements in various metabolic parameters compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy of Semaglutide 2.4 mg in adolescents with obesity, finding significant improvements in various metabolic parameters compared to placebo.
This research is crucial as it provides evidence for a new treatment option for adolescents struggling with obesity, a condition linked to numerous health risks. Effective management of obesity in this age group can lead to improved long-term health outcomes.
The study's long-term effects of Semaglutide remain unclear. Sample size and demographics may limit generalizability. Potential side effects of Semaglutide were not fully addressed.
Published in
Publication details and source links for this paper.
Silva A, Inge G, Bryan G, et al. Semaglutide 2.4 mg for Adolescents with Obesity: A Phase 3a Randomized Controlled Trial. Diabetes Care. 2026;49(6):954-962. doi:10.2337/dc25-0824
Semaglutide resulted in a -16.7 percentage point reduction in BMI compared to placebo (P = 0.0001).
Fasting insulin levels decreased by 33.6% in the Semaglutide group versus 10.1% in placebo (P = 0.0012).
HOMA-IR score decreased by 35.0% in the Semaglutide group compared to 5.3% in placebo (P = 0.0002).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Alanine Aminotransferase (ALT), Body Mass Index (BMI) change, Fasting Plasma Glucose (FPG), and 7 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
5
Related topics
10
Evidence pairs
1440
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Alanine Aminotransferase (ALT)
Semaglutide → Alanine Aminotransferase (ALT)
Semaglutide → Body Mass Index (BMI) change
Semaglutide → Body Mass Index (BMI) change
Semaglutide → Fasting Plasma Glucose (FPG)
Semaglutide → Fasting Plasma Glucose (FPG)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
12 results
3 results
12 results
12 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.6 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with generally consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body Mass Index (BMI) change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 16 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
LDL cholesterol
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Alanine Aminotransferase (ALT)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Total cholesterol
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
